National Immunobiological Company

Name

National Immunobiological Company

Legal name

Акционерное общество «Национальная иммунобиологическая компания»

Website

https://nacimbio.ru

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Vaccines and Immunobiological Products

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN), Vaccine Cold Chain, Storage & Distribution (HLAIAEAK)

Keywords

• Vaccine manufacturing
• Immunoglobulin products
• Blood plasma derivatives
• Influenza vaccines
• Pharmaceutical manufacturing

Headquarters

HQ city

Moscow

HQ country

Russia

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Government vaccine supply contracts: Supply of influenza vaccines and other immunobiological products to Russian regions under government contracts for the National Preventive Immunization Schedule
2. Blood plasma products: Supply of human blood plasma-derived products including immunoglobulins and albumin to fulfill national needs
3. COVID-Globulin: Anti-COVID-19 human immunoglobulin product for treatment of moderate coronavirus infections
4. Anti-hepatitis B product (Antigep-Neo): First Russian intravenous-specific immunoglobulin for prevention of hepatitis B

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

National Immunobiological Company (Nacimbio) is a Russian pharmaceutical holding that manufactures and supplies vaccines (influenza, hepatitis B), blood plasma-derived products (immunoglobulins, albumin), bacteriophages, botulinum toxin, and diagnostic preparations. Operations are centered on full-cycle GMP-compliant production through its two subsidiaries NPO Microgen and LLC FORT, fulfilling Russia's National Preventive Immunization Schedule primarily through government supply contracts to public medical institutions.

Product overview

National Immunobiological Company (Nacimbio) is a Russian pharmaceutical holding within Rostec State Corporation, operating as a unified platform with two major production assets: NPO Microgen (Russia's largest producer of immunobiological products, established 2003) and LLC FORT (state-of-the-art GMP-certified facility opened 2014 in Ryazan Region). The company manufactures a portfolio of influenza vaccines including Ultrix Quadri (tetravalent), Ultrix, and Sovigripp (trivalent), blood plasma products such as BioGam and COVID-Globulin, hepatitis B treatment Antigep-No, bacteriophage products (RuPhages), and botulinum toxin (Relatox). Additionally, the company offers a consumer-facing mobile app 'Прививки — личный календарь' for personal vaccination management. The product portfolio spans preventive vaccines for the National Immunization Schedule, therapeutic immunoglobulins, and antibacterial phage products, with focus on import substitution and pharmaceutical sovereignty.

Differentiator

Problem solved

Functional benefit

Brands

• Ultrix: Trivalent influenza vaccine for seasonal flu prevention
• Ultrix Quadri
• Sovigripp
• COVID-Globulin
• BioGam
• Antigep-Neo
• RuPhages

Products and services

• Ultrix Quadri First Russian tetravalent (quadrivalent) influenza vaccine meeting WHO recommendations. Contains 60 µg of total antigens (15 µg per strain), without preservatives, stabilizers, or adjuvants. Meets immunogenicity criteria accepted in EU and Russian Federation, with GMP-compliant fill-finish production in Russia.
• Sovigripp Inactivated trivalent subunit influenza vaccine used for annual prophylactic immunization against seasonal influenza. Indicated for infants from 6 months, teenagers, adults, and pregnant women (2nd-3rd trimesters). Supplied in glass vials or prefilled syringes since 2015.
• Ultrix Trivalent influenza vaccine manufactured at the FORT plant. Part of the National Preventive Immunization Schedule, with full-cycle domestic production from active substance to finished dosage form.
• COVID-Globulin Highly purified anti-COVID-19 human immunoglobulin product isolated from donor blood plasma containing SARS-CoV-2 antibodies. Used for treatment of moderate coronavirus infections as part of comprehensive therapy, administered intravenously.
• BioGam Normal human immunoglobulin presented as a 10% solution, manufactured using original patented technological platform ensuring viral safety and high degree of purification. Used for replacement or immunomodulating therapy in patients with antibody deficiency disorders, including pediatric practice, treatment of pregnant women, and patients with cardiovascular or renal pathology.
• Antigep-Neo First Russian intravenous-specific immunoglobulin for prevention of hepatitis B in both children and adults. Also indicated for patients with increased risk of hepatitis B before surgery, repeated blood transfusion, hemodialysis, and organ/cell transplantation.
• RuPhages Line of bacteriophage antibacterial products used for treatment of complex surgical infections resistant to antibiotics.
• Relatox Botulinum toxin product from Nacimbio's portfolio.
• Vaccinations — Personal Planner (Прививки — личный календарь) Mobile application providing personal vaccination calendar and handbook. Algorithm accounts for user's vaccination history, lifestyle, and creates a personal plan based on the National Immunization Schedule and Epidemic Indications Calendar. Includes push notifications, medical expert contact, vaccination news, and FAQs. Bronze Medal winner at Tagline Awards 2020-2021 in Best Medicine/Telemedicine App category.

Quantifiable outcome

• More than 24 million doses of vaccines delivered to Russian regions in H1 2026
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• FORT (ООО «ФОРТ»)coreStrategic or Co-development Partner · 1 April 2014FORT is a biopharmaceutical subsidiary specializing in development, manufacturing and marketing of biological drugs including vaccines for prevention of socially significant infectious diseases. Modern scientific industrial complex opened in April 2014 in Ryazan Region, operating at GMP standards.

Scale indicators7 records

Recent moves8 records

Expansion highlights3 records

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/national-immunobiological-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Immunobiological Company